MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Trastuzumab deruxtecan

MCE 國際站：Trastuzumab deruxtecan

品牌：MedChemExpress (MCE)

CAS：1826843-81-5

貨號：HY-138298A

Synonyms：DS-8201; DS-8201a

存儲條件：-80°C,避光保存

運輸條件：使用干冰運輸。

產品活性：Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一種抗人表皮生長因子受體 2 (HER2) 抗體-活性分子偶聯物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 抗體、酶促裂解的肽接頭、拓撲異構酶 I 抑制劑 (毒素成分 Dxd) 組成。Trastuzumab deruxtecan 可用于 HER2 陽性乳腺癌和胃癌的研究。

體外：Trastuzumab deruxtecan（1 pM-10 nM；5 天）抑制 HER2 陽性 KPL-4 細胞的生長，IC50 為 109.7 pM[2]。Trastuzumab deruxtecan（10 nM；5 天）在 HER2 陰性 MDA-MB-468 細胞中表現出旁觀者殺傷作用[2]。 MCE尚未獨立證實這些方法的準確性。僅供參考。

體內：Trastuzumab deruxtecan（3 mg/kg；單次靜脈注射）在聯合接種條件下不僅對 HER2 陽性腫瘤而且對 HER2 陰性腫瘤均顯示出抗腫瘤活性[2]。Trastuzumab deruxtecan（10 mg/kg；在第 0 天和第 7 天靜脈注射）抑制 EMT6-hHER2 同源小鼠模型中的腫瘤生長[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

銷售產品：Sitagliptin  | SB 525334  | OSS_128167  | L-Glutamine  | DL-Isocitric acid (trisodium salt)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.[2]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.[3]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.[4]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645.